Comparative Pharmacology
Head-to-head clinical analysis: AXID AR versus PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AXID AR versus PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER.
AXID AR vs PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nizatidine is a competitive, reversible inhibitor of histamine at the H2-receptors of the gastric parietal cells, reducing gastric acid secretion.
Competitive histamine H2-receptor antagonist; inhibits gastric acid secretion by blocking H2 receptors on parietal cells.
75 mg orally once daily at bedtime for heartburn relief; maximum 150 mg per 24 hours.
20 mg intravenously every 12 hours; or 40 mg intravenously once daily. For Zollinger-Ellison syndrome, initial dose 20 mg intravenously every 6 hours; adjust based on acid output.
None Documented
None Documented
Terminal elimination half-life is 1.5–2.5 hours (mean ~2 hours) in patients with normal renal function. In elderly or those with creatinine clearance <50 mL/min, half-life may extend to 4–6 hours, necessitating dose adjustment.
2.5–3.5 hours in normal renal function; prolonged to 6–8 hours in moderate renal impairment (CrCl <50 mL/min) and up to 20 hours in severe renal failure (CrCl <10 mL/min)
Primarily renal; ~60% of an oral dose is excreted unchanged in urine via tubular secretion and glomerular filtration. Hepatic metabolism accounts for ~30% (N-oxidation, S-oxidation, and N-demethylation), with metabolites and small amounts of parent drug eliminated in feces via bile.
Renal (65–70% unchanged via tubular secretion and glomerular filtration); biliary/fecal (minor, <10%)
Category C
Category C
H2 Receptor Antagonist
H2 Receptor Antagonist